ZA200808900B - Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods - Google Patents

Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Info

Publication number
ZA200808900B
ZA200808900B ZA200808900A ZA200808900A ZA200808900B ZA 200808900 B ZA200808900 B ZA 200808900B ZA 200808900 A ZA200808900 A ZA 200808900A ZA 200808900 A ZA200808900 A ZA 200808900A ZA 200808900 B ZA200808900 B ZA 200808900B
Authority
ZA
South Africa
Prior art keywords
polypeptides
inflammatory
enhanced anti
cytotoxic properties
decreased cytotoxic
Prior art date
Application number
ZA200808900A
Other languages
English (en)
Inventor
Ravetch Jeffrey
Yoshikatus Kaneko
Nimmerjahn Falk
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38581601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200808900(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of ZA200808900B publication Critical patent/ZA200808900B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200808900A 2006-04-05 2008-10-17 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods ZA200808900B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78938406P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
ZA200808900B true ZA200808900B (en) 2009-10-28

Family

ID=38581601

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808900A ZA200808900B (en) 2006-04-05 2008-10-17 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Country Status (12)

Country Link
US (14) US10167332B2 (https=)
EP (3) EP2010566B2 (https=)
JP (6) JP6084761B2 (https=)
CN (1) CN101432301B (https=)
AU (1) AU2007235413B2 (https=)
CA (1) CA2647524C (https=)
EA (1) EA022780B1 (https=)
IL (1) IL194526A (https=)
MX (1) MX2008012843A (https=)
NZ (1) NZ572379A (https=)
WO (1) WO2007117505A2 (https=)
ZA (1) ZA200808900B (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2647524C (en) * 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2011138354A1 (en) 2010-05-07 2011-11-10 Csl Behring Ag Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
JP5956982B2 (ja) 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US12384848B2 (en) 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
PT2793943T (pt) 2011-12-19 2018-11-13 Univ Rockefeller Polipéptidos anti-inflamatórios não siliados
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
CA2909139C (en) 2013-04-18 2021-07-06 Institut National De La Sante Et De La Recherche Medicale Composition with reduced immunogenicity
ES2802274T3 (es) * 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR20170040132A (ko) * 2014-06-02 2017-04-12 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 Fc 단편의 제조
EP3207055A1 (en) 2014-10-15 2017-08-23 Xenothera Composition with reduced immunogenicity
EA038554B1 (ru) 2015-03-04 2021-09-14 Зе Рокфеллер Юниверсити Противовоспалительные полипептиды
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
EP3681908A1 (en) 2017-09-13 2020-07-22 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
CN117924477A (zh) 2017-12-19 2024-04-26 洛克菲勒大学 具有改进的效应子功能的人IgG Fc结构域变体
JP2021508479A (ja) 2017-12-27 2021-03-11 テネオバイオ， インコーポレイテッド ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
DK4257600T3 (da) 2018-07-03 2025-05-26 Gilead Sciences Inc Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
US20210347848A1 (en) 2018-08-31 2021-11-11 ALX Oncology Inc. Decoy polypeptides
SG11202102713TA (en) 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
US20210353752A1 (en) * 2018-10-11 2021-11-18 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
CN110297093B (zh) * 2019-03-18 2022-04-22 山西瑞豪生物科技有限公司 一种检测人免疫球蛋白g4的方法和试剂盒
KR102549282B1 (ko) * 2019-11-18 2023-06-30 건국대학교 산학협력단 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
CN115023441A (zh) 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
JP2025542423A (ja) * 2022-12-21 2025-12-25 コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション α－２，６－シアル化免疫グロブリンの眼球乾燥症または炎症性眼疾患の予防または治療用途
CN115819560A (zh) * 2022-12-27 2023-03-21 河南赛诺特生物技术有限公司 制备第二抗体的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2097617A1 (en) 1990-11-23 1992-05-23 Brian Seed Inhibition of cell adhesion protein-carbohydrate interactions
US5453272A (en) 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US20020045207A1 (en) 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
HK1048138B (zh) * 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
DE19927835A1 (de) 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
CA2424977C (en) * 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
WO2002040047A2 (en) 2000-11-20 2002-05-23 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7427469B2 (en) 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
MXPA05006522A (es) * 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
US20070048740A1 (en) 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
EP1670821A4 (en) 2003-10-09 2006-11-29 Daewoong Co Ltd PROCESS FOR PURIFYING HUMAN THROMBOPOIETIN WITH HIGH SIALIC ACID CONTENT
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005058244A2 (en) 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
PT1896071E (pt) 2005-06-30 2015-07-09 Janssen Biotech Inc Métodos e composições com melhorias na atividade terapêutica
EP1937306B1 (en) 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolysis resistant antibody preparations
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2647524C (en) * 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007317755A1 (en) 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
NZ585530A (en) 2007-12-27 2012-06-29 Baxter Int Methods for differentiating plasma-derived protein from recombinant protein in a sample

Also Published As

Publication number Publication date
CN101432301B (zh) 2014-01-08
AU2007235413B2 (en) 2012-08-02
JP7357382B2 (ja) 2023-10-06
US10167332B2 (en) 2019-01-01
CA2647524C (en) 2019-11-26
IL194526A (en) 2012-04-30
US20170218050A1 (en) 2017-08-03
US20190031737A1 (en) 2019-01-31
JP2018118985A (ja) 2018-08-02
EA022780B1 (ru) 2016-03-31
US20140323696A1 (en) 2014-10-30
EP2010566A2 (en) 2009-01-07
AU2007235413A1 (en) 2007-10-18
JP6989979B2 (ja) 2022-02-15
JP6322849B2 (ja) 2018-05-16
US20100278808A1 (en) 2010-11-04
US20210101961A1 (en) 2021-04-08
JP2015038086A (ja) 2015-02-26
EP2010566B2 (en) 2017-07-26
IL194526A0 (en) 2011-08-01
US20170283492A1 (en) 2017-10-05
US20190127446A1 (en) 2019-05-02
US20160176950A1 (en) 2016-06-23
EP2815768A3 (en) 2015-01-14
JP2022031807A (ja) 2022-02-22
US20130273040A1 (en) 2013-10-17
JP2020117521A (ja) 2020-08-06
WO2007117505A2 (en) 2007-10-18
US20230121427A1 (en) 2023-04-20
HK1124074A1 (en) 2009-07-03
EP2010566B1 (en) 2014-09-03
JP2009532477A (ja) 2009-09-10
US20200385443A1 (en) 2020-12-10
JP2017002041A (ja) 2017-01-05
EP3456351A1 (en) 2019-03-20
CN101432301A (zh) 2009-05-13
EP2010566A4 (en) 2010-05-05
EA200870411A1 (ru) 2009-04-28
JP6686058B2 (ja) 2020-04-22
US20170320935A1 (en) 2017-11-09
JP6084761B2 (ja) 2017-02-22
MX2008012843A (es) 2009-01-19
US20190031738A1 (en) 2019-01-31
NZ572379A (en) 2012-06-29
EP2815768A2 (en) 2014-12-24
CA2647524A1 (en) 2007-10-18
US20170088608A1 (en) 2017-03-30
WO2007117505A3 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
IL194526A0 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
IL206029A0 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
IL237314A (en) Insulin polypeptides are modified and their uses
IL185563A0 (en) Gip analog and hybrid polypeptides with selectable properties
EP2089480A4 (en) ANTIMICROBIAL MATERIALS AND ANTIMICROBIAL COATINGS
IL193198A0 (en) Long-actine polypeptides and methods of producing and administering same
IL194751A0 (en) Drugs and uses
PL2064327T3 (pl) Dbait i ich zastosowania
ZA200902161B (en) Antiobodies and immunoconjugates and uses therefor
ZA200904061B (en) Fuel composition and its use
GB0720579D0 (en) Functionalised materials and uses thereof
IL197920A0 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
ZA200903906B (en) Carboranylporphyrins and uses thereof
SI2068909T1 (sl) Modificirani fgf-21 polipeptidi in njihova uporaba
IL195525A0 (en) Replikin peptides and uses thereof
ZA200904583B (en) Dual composition with warming and analgesic effects
GB0621513D0 (en) Novel polypeptides and uses thereof
EP1977996A4 (en) PHOSPHATE METAL-CONTAINING COMPLEX AND THIS CONTAINING SEALED MATERIAL
GB0607798D0 (en) Novel polypeptides and use thereof
PL2032708T3 (pl) Rekombinowane nowirabdowirusy i ich zastosowania
HK1135408A (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
HK1148933A (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
GB0701295D0 (en) Z-stilbenes derivatives and the pharmaceutical composition thereof
GB0907108D0 (en) Mutants and uses therefor
IL192800A0 (en) Fgf2-binding peptides and uses thereof